脑机接口产业发展突破有了“施工图”

Core Insights - The Chinese government has accelerated the introduction of favorable measures for implantable brain-machine interface medical devices in 2023, including pricing guidelines for invasive procedures [1] - The establishment of pricing for invasive brain-machine interface procedures, such as a placement fee of 6,580 yuan and a removal fee of 3,150 yuan, is expected to stimulate market growth [1] - China has entered the clinical trial phase for implantable brain-machine interfaces, becoming the second country globally to do so after the United States [1] Industry Developments - The National Healthcare Security Administration issued guidelines for pricing on neuro-system medical services, which include invasive brain-machine interface procedures [1] - The successful completion of China's first prospective clinical trial for implantable brain-machine interfaces marks a significant milestone in the country's technological advancement in this field [1] Market Implications - The clarification of pricing is seen as a breakthrough that will facilitate the application of new technologies and create new market opportunities [1] - Collaboration among technology developers, clinical institutions, capital, and government is essential for the successful incubation and implementation of research outcomes in brain science [1] - Startups in the brain-machine interface sector need to balance short-term survival with long-term innovation goals to maintain investment in core technology development [1]